Introduction
Macrophage activation syndrome (MAS) is a hyperinflammatory syndrome, associated usually with systemic juvenile idiopathic arthritis and adult-onset Still's disease (AOSD) [1] [2] [3] [4] . Due to this close association, it has been suggested that MAS and AOSD may represent one part of the same disease spectrum, of which AOSD may be considered the milder form [5] . In this context, it has been shown that MAS occurrence may be misdiagnosed due to immunosuppressive drugs used to treat AOSD flare, thus reducing the reported prevalence of this syndrome [6, 7] . Furthermore, patients affected by systemic lupus erythematosus (SLE) may also experience MAS [8] . Continuous high fever, hepatosplenomegaly, severe peripheral blood cytopenia and haemophagocytosis by activated macrophages in bone marrow (BM) are typical features of these patients [1] [2] [3] [4] [5] [6] [7] [8] . In contrast to paediatric patients, the therapeutic strategies of adults derive mainly from case-series and retrospective experiences [9] [10] [11] . In this context, the clearance of possible triggers, immunosuppressive therapeutic strategies and supportive care are considered the main therapeutic strategies [10] . Despite aggressive therapeutic strategies, MAS is one of the most critical clinical disorders in adults, evolving to multiple organ failure and unfavourable outcome [1, 8] . This result may be possibly related, in adult age, with an increased presence of co-morbidities, the latter known to be predictive of a more severe outcome in MAS patients as observed in other rheumatic diseases [3, 8, 12] .
Recently, a multi-layer MAS pathogenic model during inflammatory rheumatic diseases has been proposed [2] . Genetic factors, proinflammatory milieu associated with the underlying rheumatic disease, trigger factors and the uncontrolled activation of macrophages and T cells may lead to the development of cytokine storm and MAS [13, 14] . Activation of cytotoxic CD8 T lymphocytes with production of macrophage-activating cytokines, such as interferon (IFN)-g, is an early event in MAS pathogenesis. Defects in granulocyte-mediated cytotoxicity, enhanced antigen presentation and repeated stimulation of Toll-like receptors determine extensive production/release of tumour necrosis factor (TNF) and interleukin (IL)-1b [13, 14] . The consequent activation and expansion of monocytes and macrophages lead to pathological haematophagocytosis [1, 2, 13, 14] . In this context, it has been considered that macrophages are categorized in M1 (classically activated), releasing proinflammatory mediators, and M2 (alternatively activated), modulating the inflammatory response [15] .
During MAS, a possible pathogenic role of ferritin has been suggested and has been included in the so-called 'hyperferritinaemic syndrome' [16, 17] . Ferritin is an intracellular iron storage protein including 24 subunits. These are categorized, according to molecular weight, as heavy (H) subunits and light (L) subunits. Ferritin enriched in L subunits (L-ferritin) has been found in liver and in spleen, whereas ferritin enriched in H subunits (H-ferritin) may be observed mainly in heart and kidneys [17] . Possible causes of hyperferritinaemia in these patients include increased production to sequestrate free iron of released haemoglobin due to erythrophagocytosis, reduced tissue clearance and enhanced production by macrophages [16, 17] .
In this study, we aimed to investigate H-and L-ferritin in inflammatory BM infiltrate of MAS patients during fullblown syndrome. Macrophage subsets expressing H-and L-ferritin were also assessed. Furthermore, we evaluated IL-1b, TNF, IFN-g and their possible co-localization with ferritin within inflammatory cells. Finally, any possible clinical correlation of these data with the severity of the disease was analysed.
Patients and methods
A retrospective evaluation of BM biopsies obtained from adult MAS patients admitted to the Rheumatology Clinic of L'Aquila University and Rheumatology Clinic of Palermo University during the last 10 years was performed. MAS patients were diagnosed according to 2004 haemophagocytic lymphohistiocytosis (HLH) diagnostic guidelines criteria [18] . In this study, we also evaluated 10 biopsies derived from BM-donors, used as healthy controls (HCs).
For each patient we analysed age, gender, values of white blood cell count (WBC), red blood cells (RBC), haemoglobin (HB), platelet count (PLT), serum ferritin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) during the full-blown syndrome.
The local ethics committee approved the study (ASL1 Avezzano-Sulmona-L'Aquila, L'Aquila, Italy, protocol number 0122353/17) that was performed according to Good Clinical Practice guidelines and Declaration of Helsinki.
Histological analysis of biopsies
Samples were stained with anti-H-ferritin, anti-L-ferritin, anti-CD68, anti-CD163, anti-IL-1b, anti-IL-12, anti-IFN-g and anti-TNF antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), as reported previously [16] . Samples were acquired using a light microscope (Olympus BX53) and immunofluorescence images by CellSens software (Olympus America Inc., Center Valley, PA, USA). Cells double-positive for both CD68/H-ferritin and CD68/L-ferritin were counted in sections from randomly selected areas of the BM, counting at least 500 nucleated cells (320 magnification) by using NIHimageJ version 1.43 (http://rsbweb.nih.gov/ij/) freeware.
Statistical analysis
To compare the results of MAS patients and HCs, the Mann-Whitney U-test was considered appropriate due to the non-parametric distribution of our data. To assess correlations among tissue H-and L-ferritin, the numbers of double-positive cells for CD68 and H-ferritin (CD68 
Results

Demographic and clinical features
In this study, we evaluated BM biopsies of 10 patients affected by MAS collected during the full-blown syndrome. All these adult patients were affected by proinflammatory rheumatic disease (eight patients by AOSD, two patients by SLE), and MAS occurred during disease flare or severe infection. We observed that two patients experienced MAS after severe Epstein-Barr virus (EBV) infection and two patients during Gram-negative sepsis, due to immunosuppressive treatments administered for underlying rheumatic disease. All these patients showed peripheral blood cytopenia [WBC, mean 6 standard deviation (s.d.) 3Á23 6 1Á44, 10
H-ferritin is increased in BM and correlates with clinical features
We observed a granular morphological pattern of H-ferritin and L-ferritin immunoreactivity, including cytoplasmatic and extracellular localization, using immunofluorescence. As shown in Fig. 1 , H-ferritin was increased in BM samples of MAS patients when compared with both L-ferritin and HCs (P < 0Á0001 for each comparison), analysing the optical density of immunofluorescence. Conversely, L-ferritin was not increased when compared to HCs. Subsequently, clinical correlations among these histological data and severity of the clinical picture were evaluated. Our analyses showed that the peripheral blood cytopenia of these patients were correlated inversely with the levels of H-ferritin in the BM of MAS. Increased values of H-ferritin levels correlated with decreased WBC and PLT counts (P 5 0Á01, P 5 0Á0001; respectively). A further correlation was observed among tissue H-ferritin and the inflammatory markers. H-ferritin was correlated statistically with both serum ferritin and CRP levels (P 5 0Á012; P 5 0Á0058, respectively), as shown in Fig. 2 . No correlation was observed among RBC count, levels of HB, ESR, ASAT, ALAT and H-ferritin. The correlations among L-ferritin and clinical data did not show significant results.
IL-1b, TNF, IFN-g and H-ferritin
Proinflammatory cytokines were increased significantly in BM samples of MAS patients when compared with HCs analysing the immunofluorescence of our samples. Specifically, a marked increase of IL-1b was observed in BM of MAS patients (P 5 0Á0002). In addition, the analyses showed a significant correlation between the tissue expression of H-ferritin and IL-1b (P 5 0Á006). Interestingly, H-ferritin and IL-1b co-localized in the BM samples of our patients, as shown in Fig. 3 . ALAT 5alanine aminotransferase; AOSD 5 adult-onset Still's disease; ASAT 5aspartate aminotransferase; CRP 5 C-reactive protein; ESR 5 serum ferritin, erythrocyte sedimentation rate; HB 5 haemoglobin; MAS 5 macrophage activation syndrome; PLT 5 platelet count; RBC 5 red blood cells; SLE 5 systemic lupus erythematosus; WBC 5 white blood cell count.
Furthermore, we showed a significant increase of TNF in the BM of evaluated patients when compared with HCs (P 5 0Á002) (Fig. 4) . Similarly, a marked increase of IFN-g was observed when compared with HCs (P < 0Á0001). However, we did not report correlation or co-localization among these proinflammatory cytokines and H-ferritin.
CD68
1 /H-ferritin 1 macrophages are increased and correlate with clinical features
In our MAS patients, we reported that H-ferritin co-localized with CD68, as shown in Fig. 5 . Furthermore, macrophages expressing H-ferritin in the inflammatory infiltrate were increased significantly when compared with HCs (P 5 0Á006) (Fig. 5) . In the same samples, although we observed a weak co-localization between CD68 and L-ferritin, these cells did not differ significantly when compared with HCs. We analysed and compared the number of CD68 1 cells 1Á7 median, range 5 1Á5; 2Á2; P < 0Á0001). In addition, we analysed possible co-localizations among the H-ferritin and IL-12, which is considered an M1 macrophage marker, and CD163, which is considered an M2 macrophage marker, as shown previously [19, 20] . As shown in Fig. 5, a patients correlated with reduced WBC and the PLT counts (P 5 0Á03, P 5 0Á0007, respectively). Furthermore, CD68
1 / H-ferritin 1 cells were correlated significantly with both serum ferritin and CRP levels (P 5 0Á0088; P 5 0Á049; respectively). Figure 6 shows these statistical analyses. ESR, RBC count and HB levels did not correlate with CD68 
Discussion
In our study, H-ferritin, CD68 (c) IFN-g was increased significantly when MAS patients were compared with HCs (***P < 0Á001); (d) increased TNF (green) levels and H-ferritin (red) may be observed in MAS; (e) reduced TNF levels in HCs; (f) TNF was increased significantly when MAS patients were compared with HCs (***P < 0Á001). were correlated significantly with the haematological involvement of our patients, suggesting possible biomarkers of severity. During MAS, the massive release/production of proinflammatory cytokines may induce H-ferritin expression by activation of specific transcription factors, such as ferritin 2 (FER2), which may in turn activate production of further proinflammatory cytokines, triggering a possible vicious loop [21] [22] [23] [24] [25] [26] . In fact, we observed high H-ferritin in the BM of MAS patients and co-localization as well as a correlation between H-ferritin and IL-1b, a possibly therapeutic target in MAS and rheumatic diseases [27] [28] [29] [30] [31] . Furthermore, a specific receptor for H-ferritin on immune cells has also been reported [32] . The specific binding between H-ferritin and the T cell immunoglobulin and mucin domain-containing protein-2 (TIM-2) receptor may modulate the inflammatory process. This is a member of the TIM gene family and is expressed by T helper type 2 (Th2) cells and macrophages in the context of the proinflammatory milieu [32, 33] . The binding H-ferritin/TIM-2 may activate these immune cells, leading to subsequent pathogenic proinflammatory process [12, [18] [19] [20] [21] . Taking together all these mechanisms, it is possible to speculate that the enhanced tissue expression of H-ferritin, via a vicious loop, may perpetuate the production of proinflammatory cytokines, possible therapeutic targets in MAS [16, 17, 22, 23, 27, 28] .
In our samples, we described macrophages co-expressing CD68 and H-ferritin that were increased in the BM infiltrate of MAS. These data may confirm that, after proinflammatory stimuli, macrophages may release H-ferritin, confirming their role in ferritin production [34] . Interestingly, H-ferritin co-localized with IL-12, a marker of M1-macrophages, associated with increased production of proinflammatory molecules. Macrophages are polarized by environment, mainly the cytokine milieu, towards distinct functional programmes, categorized as M1 and M2 pathways. Massive production of IL-1b, INF-g and TNF may promote the recruitment and proliferation of M1 macrophages; persistent and uncontrolled expansion of these proinflammatory macrophages is a pivotal mechanism in MAS development [35, 36] .
To date, H-ferritin and CD68 1 /H-ferritin 1 cells were correlated significantly with haematological involvement, serum ferritin and CRP of our MAS patients. These results suggest potentially new biomarkers evaluating severity of the MAS clinical picture, possibly improving outcome in these patients [37, 38] . In fact, diagnosis and appropriate treatments may be delayed, due to non-specific findings in the early phases of disease, thus new biomarkers may improve the management of this life-threating syndrome [39] [40] [41] [42] . Although a rigorous process of validation is needed, the use of novel biomarkers in these patients may help physicians, thus improving diagnosis with early recognition and prompt therapy as well as predicting response to treatment and outcome, as suggested in other rheumatic diseases [43] [44] [45] [46] [47] . Our retrospective study shows different limitations. We evaluated a low number of patients, thus our findings should be confirmed further. However, it must be pointed out that MAS is a very rare disease and, as observed for other infrequent complications during rheumatic diseases, organizing specifically designed studies may be a challenge [48] [49] [50] . Furthermore, our study did not allow us to indicate if the CD68 1 macrophages are actively producing ferritin or phagocyting cells and future specifically designed studies are needed to elucidate these pathogenic steps entirely during MAS.
In conclusion, H-ferritin, CD68 
